List – 91 Drug Patents that are Expiring between 2020 to 2022
Atrovant HFA
Ipratropium Bromide
Sales:
$135 million (2014)
Patents | Expiration Date |
---|---|
US6739333 | May 26, 2020 |
US6983743 | May 26, 2020 |
Dosage : Aerosol, Metered; Inhalation
Company : Boehringer Ingelheim Pharmaceuticals Inc
Ingredients : Ipratropium Bromide
Treatment : Chronic Obstructive Pulmonary Disease and Asthma
ANDA Filing Company : –
Byduredon BCISE
Exenatide
Sales:
$283 million (H1,2019)
Patents | Expiration Date |
---|---|
US6414126 | October 04, 2020 |
US6479065 | August 10, 2020 |
US6515117 | October 04, 2020 |
US6667061 | May 25, 2020 |
US6872700 | January 14, 2020 |
US6936590 | October 04, 2020 |
US9198925 | October 04, 2020 |
Dosage : Suspension, Extended Release, Subcutaneous
Company : Astrazeneca Ab
Ingredients : Exenatide
Treatment : Type 2 Diabetes Mellitus
ANDA Filing company : –
Chantix
Varenicline
Sales:
$1.08 billion (2018)
Patents | Expiration Date |
---|---|
US6410550 | November 10, 2020 |
Dosage : Tablet; Oral
Company : Pfizer
Ingredients : Varenicline Tartrate
Treatment : Smoking Cessation
ANDA Filing Companies : Mylan, Ajanta Pharma, Par Pharma, Apotex
Dexilant
Dexlansoprazole
Sales:
$445 Million (2017)
Patents | Expiration Date |
---|---|
US6462058 | December 15, 2020 |
US6939971 | December 15, 2020 |
US7285668 | December 15, 2020 |
US9145389 | June 15, 2020 |
Dosage : Capsule, Delayed Release; Oral
Company : Takeda Pharmaceuticals Usa Inc
Ingredients : Dexlansoprazole
Treatment : Erosive Esophagitis
ANDA Filing Companies : Dr Reddy’s, Impax, Anchen, Twi Pharma
Inlyta
Axitinib
Sales:
$339 million (2017)
Patents | Expiration Date |
---|---|
US7141581 | June 30, 2020 |
Dosage : Tablet; Oral
Company : Pfizer
Ingredients : Axitinib
Treatment : Advanced Renal Cell Carcinoma
ANDA Filing Companies : Apotex, Glenmark
Safyral
Drospirenone; Ethinyl Estradiol; Levomefolate
Sales:
$22 million (2017)
Patents | Expiration Date |
---|---|
US6441168 | April 17, 2020 |
Dosage : Tablet; Oral
Company : Bayer Healthcare Pharmaceuticals Inc
Ingredients : Drospirenone; Ethinyl Estradiol; Levomefolate Calcium
Treatment : Oral Contraceptive
ANDA Filing Companies : Lupin, Watson
Saphris
Asenapine
Sales:
$139.7 million (2018)
Patents | Expiration Date |
---|---|
US5763476 | December 09, 2020 |
Dosage : Tablet; Sublingual
Company : Allergan Llc
Ingredients : Asenapine Maleate
Treatment : Antipsychotic
ANDA Filing Companies : Alembic, Amneal, Breckenridge, Hikma, SigmaPharma
Silenor
Doxepin
Sales:
$22.3 million (2017)
Patents | Expiration Date |
---|---|
US6211229 | February 17, 2020 |
Dosage : Tablet; Sublingual
Company : Currax Pharmaceuticals Llc
Ingredients : Doxepin Hydrochloride
Treatment : Sleep Problem (Insomnia)
ANDA Filing Companies : Par Pharma, Actavis, Mylan, Zydus Cadila
Sprycel
Dasatinib
Sales:
$536 million (2018)
Patents | Expiration Date |
---|---|
US6596746 | December 28, 2020 |
US7125875 | October 13, 2020 |
US7153856 | October 28, 2020 |
Dosage : Tablet; Oral
Company : Bristol Myers Squibb Co
Ingredients : Dasatinib
Treatment : Cancer (chronic myeloid leukemia-CML, acute lymphoblastic leukemia-ALL
ANDA Filing Companies : Apotex, Dr Reddy’s
Vigamox
Moxifloxacin
Sales:
$267.9 million (2017)
Patents | Expiration Date |
---|---|
US6716830 | March 29, 2020 |
US7671070 | March 29, 2020 |
Dosage : Solution/Drops; Ophthalmic
Company : Novartis Pharmaceuticals Corp
Ingredients : Moxifloxacin Hydrochloride
Treatment : Bacterial Conjunctivitis
ANDA Filing Companies : Teva, Watson, Lupin, Apotex, Aurobindo, Akorn, Alembic
Xarelto
Rivaroxaban
Sales:
$6.58 billion (2018)
Patents | Expiration Date |
---|---|
US7585860 | December 11, 2020 |
US7592339 | June 24, 2022 |
Dosage : Tablet; Oral
Company : Janssen Pharmaceuticals Inc
Ingredients : Rivaroxaban
Treatment : Stroke and systemic embolism with nonvalvular atrial fibrillation
ANDA Filing Companies : Aurobindo, Breckenridge, Microlabs, Mylan, SigmaPharma, Torrent, Prinston Pharma, Sun (Taro), Teva, Alembic, Invagen, Lupin, Macleods, Accord (Intas), Hec Pharma
Bystolic
Nebivolol
Sales:
$585.8 million (2018)
Patents | Expiration Date |
---|---|
US6545040 | December 17, 2021 |
Dosage : Tablet; Oral
Company : Allergan Llc
Ingredients : Nebivolol Hydrochloride
Treatment : Hypertension
ANDA Filing Companies : Amerigen Pharma, Glenmark, Hetero, Torrent, Watson, Alkem, Aurobindo
Crixivan
Indinavir
Sales:
–
Patents | Expiration Date |
---|---|
US6689761 | February 10, 2021 |
Dosage : Capsule; Oral
Company : Merck Sharp And Dohme Corp
Ingredients : Indinavir Sulfate
Treatment : HIV
ANDA Filing company : –
Emtriva
Emtricitabine
Sales:
$15 million (2018)
Patents | Expiration Date |
---|---|
US6642245 | May 04, 2021 |
US6703396 | September 09, 2021 |
Dosage : Capsule; Oral
Company : Gilead Sciences Inc
Ingredients : Emtricitabine
Treatment : Combination with other antiretroviral agents, for the treatment of HIV-1 infection
ANDA Filing Companies : Cipla, Aurobindo
Hysingla ER
Hydrocodone er
Sales:
$447 million (2017)
Patents | Expiration Date |
---|---|
US6733783 | October 30, 2021 |
US8361499 | October 30, 2021 |
US8551520 | October 30, 2021 |
US8647667 | October 30, 2021 |
Dosage : Tablet, Extended Release; Oral
Company : Purdue Pharma Lp
Ingredients : Hydrocodone Bitartrate
Treatment : Severe Pain, Opioid (narcotic) Analgesics
ANDA Filing Companies : Alvogen, Mylan
Perforomist
Formoterol
Sales:
–
Patents | Expiration Date |
---|---|
US6667344 | June 22, 2021 |
US6814953 | June 22, 2021 |
US7348362 | June 22, 2021 |
US7462645 | June 22, 2021 |
US8623922 | June 22, 2021 |
US9730890 | June 22, 2021 |
Dosage : Solution; Inhalation
Company : Mylan Specialty Lp
Ingredients : Formoterol Fumarate
Treatment : Chronic Obstructive Pulmonary Disease including Chronic Bronchitis and Emphysema
ANDA Filing Company : Teva
Sutent
Sunitinib
Sales:
$264 million (2018)
Patents | Expiration Date |
---|---|
US6573293 | August 15, 2021 |
US7125905 | August 15, 2021 |
US7211600 | June 22, 2021 |
Dosage : Capsule; Oral
Company : Pfizer
Ingredients : Sunitinib Malate
Treatment : Cancer (kidney, pancreas, and intestinal)
ANDA Filing Company : Mylan
Zomig ns
Zolmitriptan
Sales:
$43.1 million (2018)
Patents | Expiration Date |
---|---|
US6750237 | May 28, 2021 |
US7220767 | May 28, 2021 |
Dosage : Spray; Nasal
Company : Astrazeneca Pharmaceuticals Lp
Ingredients : Zolmitriptan
Treatment : Migraine
ANDA Filing Companies : Lannett, Par Pharma
Januvia
Sitagliptin
Sales:
$3.68 billion (2018)
Patents | Expiration Date |
---|---|
US6699871 | July 26, 2022 |
US7125873 | July 26, 2022 |
Dosage : Tablet; Oral
Company : Merck Sharp And Dohme Corp
Ingredients : Sitagliptin Phosphate
Treatment : Type 2 Diabetes Mellitus
ANDA Filing Companies : Apotex, Mylan, Sandoz, Sun Pharma, Teva, Watson, Zydus Cadila
Pristiq
Desvenlafaxine
Sales:
$206 million (2018)
Patents | Expiration Date |
---|---|
US6673838 | March 01, 2022 |
US8269040 | July 5, 2027 |
Dosage : Tablet, Extended Release; Oral
Company : Pfizer
Ingredients : Desvenlafaxine Succinate
Treatment : Major Depressive Disorder
ANDA Filing Companies : Anchen, Apotex, Dr Reddy’s, Lupin, Mylan, Roxane, Sandoz, Teva, Watson, Intelli Pharma, Wockhardt, Zydus Cadila, Alembic (Breckenridge)
Vimovo
Esomeprazole/Naproxen
Sales:
$67.6 million (2018)
Patents | Expiration Date |
---|---|
US8557285 | May 31, 2022 |
US8852636 | May 31, 2022 |
US8858996 | May 31, 2022 |
US9161920 | May 31, 2022 |
US9198888 | May 31, 2022 |
US9345695 | May 31, 2022 |
US9707181 | May 31, 2022 |
Dosage : Tablet, Delayed Release; Oral
Company : Horizon Medicines Llc
Ingredients : Esomeprazole Magnesium; Naproxen
Treatment : Osteoarthritis, Rheumatoid Arthritis and Ankylosing Spondylitis
ANDA Filing Companies : –
Vimpat
Lacosamide
Sales:
€ 1.1 billion (2018)
Patents | Expiration Date |
---|---|
USRE38551 | March 17, 2022 |
Dosage : Tablet; Oral
Company : Ucb Inc
Ingredients : Lacosamide
Treatment : Epilepsy and Partial-onset Seizures
ANDA Filing Companies : Alembic, Amneal, Aurobindo, Breckenridge, Glenmark, Hetero, Mylan, Sandoz, Sun (Ranbaxy), Teva, Watson, Zydus Cadila
Givlaari
Givosiran
Sales:
$55 Million (2020)
Patents | Expiration Date |
---|---|
US8546143 | January 9, 2022 |
US9708610 | January 1, 2024 |
US10273477 | March 8, 2024 |
US9708615 | March 8, 2024 |
US9150605 | August 28, 2025 |
US10131907 | August 24, 2028 |
US8828956 | December 4, 2028 |
US8106022 | December 12, 2029 |
US10125364 | March 15, 2033 |
US9133461 | May 14, 2033 |
US10119143 | October 3, 2034 |
US11028392 | October 3, 2034 |
Dosage: Subcutaneous injection
Company: Alnylam Pharmaceuticals
Ingredients: GIVOSIRAN SODIUM
Treatment: Acute Hepatic Porphyria
Fusilev
Levoleucovorin
Sales:
$400K (2018)
Patents | Expiration Date |
---|---|
US6500829 | March 7, 2022 |
Dosage: Subcutaneous injection
Company: Spectrum Pharma
Ingredients: LEVOLEUCOVORIN CALCIUM
Treatment: Methotrexate
Leqvio
Inclisiran
Sales:
–
Patents | Expiration Date |
---|---|
US9074213 | March 9, 2022 |
US8232383 | February 20, 2023 |
US11078485 | November 4, 2023 |
US10669544 | March 8, 2024 |
US8809292 | May 10, 2027 |
US9370582 | December 4, 2028 |
US10806791 | December 4, 2028 |
US10125369 | August 18, 2034 |
Dosage: Subcutaneous injection
Company: Novartis
Ingredients: INCLISIRAN SODIUM
Treatment: Atherosclerotic Cardiovascular Disease and Heterozygous Familial Hypercholesterolemia
Lexiscan
Regadenoson
Sales:
$694 Million (2019)
Patents | Expiration Date |
---|---|
US6403567 | April 10, 2022 |
US8106183 | February 2, 2027 |
Dosage: Intravenous injection
Company: Astellas Pharma
Ingredients: REGADENOSON
Treatment: Myocardial Perfusion Imaging
Teflaro
Ceftaroline fosamil
Sales:
$153 Million (2019)
Patents | Expiration Date |
---|---|
US6417175 | April 11, 2022 |
Dosage: Intravenous injection
Company: Allergan
Ingredients: CEFTAROLINE FOSAMIL
Treatment: Methicillin-resistant Staphylococcus Aureus (MRSA)
Combigan
Brimonidine / Timolol
Sales:
$522 Million (2019)
Patents | Expiration Date |
---|---|
US7642258 | April 19, 2022 |
Dosage: Eye Drops
Company: Allergan
Ingredients: BRIMONIDINE TARTRATE; TIMOLOL MALEATE
Treatment: Glaucoma
Cerdelga
Eliglustat
Sales:
€219 million (2020)
Patents | Expiration Date |
---|---|
US6916802 | April 29, 2022 |
US7196205 | June 26, 2026 |
Dosage: Oral
Company: Genzyme Corporation
Ingredients: ELIGLUSTAT TARTRATE
Treatment: Gaucher’s disease
Lynparza
Olaparib
Sales:
$1.78 Billion (2020)
Patents | Expiration Date |
---|---|
US7151102 | April 29, 2022 |
US7449464 | October 11, 2024 |
US7981889 | October 11, 2024 |
US8247416 | September 24, 2028 |
Dosage: Oral
Company: AstraZeneca
Ingredients: OLAPARIB
Treatment: BRCA-mutated Advanced Ovarian Cancer
Epidiolex
Cannabidiol
Sales:
$463.6 million (2021)
Patents | Expiration Date |
---|---|
US10195159 | May 7, 2022 |
US11096905 | October 14, 2035 |
US11207292 | April 26, 2039 |
Dosage: Oral, Inhaled
Company: Greenwich Biosciences
Ingredients: CANNABIDIOL
Treatment: Seizures Associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis
Fycompa
Perampanel
Sales:
$401 million (2018)
Patents | Expiration Date |
---|---|
US6949571 | June 8, 2022 |
US8772497 | July 1, 2026 |
Dosage: Oral
Company: Eisai Inc.
Ingredients: PERAMPANEL
Treatment: Partial Seizures and Generalized tonic-clonic seizures
Trulance
Plecanatide
Sales:
$82 Million (2020)
Patents | Expiration Date |
---|---|
US7799897 | June 9, 2022 |
US7041786 | January 30, 2028 |
US10011637 | June 5, 2034 |
Dosage: Oral
Company: Salix Pharmaceuticals
Ingredients: PLECANATIDE
Treatment: Chronic Idiopathic Constipation and Irritable Bowel Syndrome
Pepaxto
Melphalan flufenamide
Sales:
–
Patents | Expiration Date |
---|---|
US6992207 | June 25, 2022 |
Dosage: –
Company: Oncopeptides
Ingredients: MELPHALAN FLUFENAMIDE HYDROCHLORIDE
Treatment: Multiple Myeloma
Caprelsa
Vandetanib
Sales:
–
Patents | Expiration Date |
---|---|
USRE42353 | June 27, 2022 |
Dosage: Oral
Company: Genzyme Corporation
Ingredients: VANDETANIB
Treatment: Medullary thyroid cancer
Stivarga
Regorafenib
Sales:
€411 Million (2019)
Patents | Expiration Date |
---|---|
US7351834 | June 28, 2022 |
US8637553 | February 16, 2031 |
US9957232 | July 9, 2032 |
Dosage: Oral
Company: Bayer
Ingredients: REGORAFENIB
Treatment: Metastatic Colorectal Cancer
Lusedra
Fospropofol
Sales:
–
Patents | Expiration Date |
---|---|
US6204257 | July 1, 2022 |
Dosage: Intravenous
Company: Eisai Inc.
Ingredients: FOSPROPOFOL DISODIUM
Treatment: Used in Diagnostic or Therapeutic procedures such as Endoscopy
Folotyn
Pralatrexate
Sales:
$48 Million (2018)
Patents | Expiration Date |
---|---|
US6028071 | July 16, 2022 |
Dosage: Intravenous
Company: Acrotech Biopharma
Ingredients: PRALATREXATE
Treatment: Relapsed or refractory peripheral T-cell lymphoma
Velcade
Bortezomib
Sales:
$930 Million (2020)
Patents | Expiration Date |
---|---|
US6958319 | July 25, 2022 |
US6713446 | July 25, 2022 |
Dosage: Intravenous
Company: Takeda
Ingredients: BORTEZOMIB
Treatment: Multiple myeloma and mantle cell lymphoma
Slynd
Drospirenone
Sales:
$30 Million (2020)
Patents | Expiration Date |
---|---|
US6441168 | July 30, 2022 |
Dosage: Oral
Company: Exeltis USA, Inc.
Ingredients: DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM
Treatment: Birth control pills to prevent pregnancy
Macrilen
Macimorelin
Sales:
–
Patents | Expiration Date |
---|---|
US6861409 | August 1, 2022 |
Dosage: Oral
Company: Æterna Zentaris
Ingredients: MACIMORELIN ACETATE
Treatment: Growth hormone deficiency
Addyi
Flibanserin
Sales:
–
Patents | Expiration Date |
---|---|
US7420057 | August 1, 2022 |
Dosage: Oral
Company: Sprout Pharmaceuticals
Ingredients: FLIBANSERIN
Treatment: Pre-menopausal women with hypoactive sexual desire disorder
Nucynta
Tapentadol
Sales:
$239.5 million (2017)
Patents | Expiration Date |
---|---|
USRE39593 | August 5, 2022 |
US7994364 | June 27, 2025 |
Dosage: Oral
Company: Collegium Pharmaceutical
Ingredients: TAPENTADOL HYDROCHLORIDE
Treatment: Moderate to severe pain for both acute and chronic musculoskeletal pain
Bylvay
Odevixibat
Sales:
$7 Million (2021)
Patents | Expiration Date |
---|---|
US7132416 | September 5, 2022 |
US10975046 | June 20, 2039 |
Dosage: Oral
Company: Albireo Pharma
Ingredients: ODEVIXIBAT
Treatment: Progressive familial intrahepatic cholestasis
Abilify
Aripiprazole
Sales:
$332 Million (2020)
Patents | Expiration Date |
---|---|
US8993761 | September 5, 2022 |
US9359302 | September 25, 2022 |
US8642760 | March 25, 2023 |
US8580796 | March 25, 2023 |
US8399469 | June 29, 2025 |
US10112903 | June 24, 2030 |
US8431576 | October 26, 2030 |
Dosage: Oral
Company: Otsuka America Pharmaceutical
Ingredients: ARIPIPRAZOLE
Treatment: Schizophrenia and bipolar disorder
Myrbetriq
Mirabegron
Sales:
$1.5 Billion (2018)
Patents | Expiration Date |
---|---|
US6346532 | September 27, 2022 |
US7342117 | May 4, 2024 |
Dosage: Oral
Company: Astellas Pharma
Ingredients: MIRABEGRON
Treatment: Overactive bladder
Lupkynis
Voclosporin
Sales:
$45.5 Million (2021)
Patents | Expiration Date |
---|---|
US7332472 | October 17, 2022 |
Dosage: Oral
Company: Aurinia Pharmaceuticals
Ingredients: VOCLOSPORIN
Treatment: Attack of lupus nephritis
Movantik
Naloxegol
Sales:
$96 Million (2019)
Patents | Expiration Date |
---|---|
US7662365 | October 18, 2022 |
US7786133 | September 16, 2028 |
US9012469 | April 2, 2032 |
Dosage: Oral
Company: AstraZeneca
Ingredients: NALOXEGOL OXALATE
Treatment: Opioid-induced constipation
Neurontin
Gabapentin
Sales:
–
Patents | Expiration Date |
---|---|
US8048917 | November 6, 2022 |
US6818787 | April 6, 2025 |
US8026279 | November 10, 2026 |
Dosage: Oral
Company: Pfizer
Ingredients: GABAPENTIN ENACARBIL
Treatment: Partial seizures and neuropathic pain
Chantix
Varenicline
Sales:
$1.1 Billion (2019)
Patents | Expiration Date |
---|---|
US6890927 | November 6, 2022 |
US7265119 | February 3, 2023 |
Dosage: Nasal spray
Company: Pfizer
Ingredients: VARENICLINE TARTRATE
Treatment: Smoking cessation
Ocaliva
Obeticholic acid
Sales:
$363.5 million (2021)
Patents | Expiration Date |
---|---|
US7138390 | November 16, 2022 |
USRE48286 | February 21, 2027 |
US10174073 | June 17, 2033 |
Dosage: Oral
Company: Intercept Pharmaceuticals
Ingredients: OBETICHOLIC ACID
Treatment: Primary biliary cholangitis
Norvasc
Amlodipine
Sales:
$363.5 million (2021)
Patents | Expiration Date |
---|---|
US6828339 | November 20, 2022 |
US6696481 | April 15, 2023 |
US7846961 | October 5, 2029 |
Dosage: Oral
Company: VIATRIS
Ingredients: AMLODIPINE BESYLATE
Treatment: High blood pressure and coronary artery disease
Viibryd
Vilazodone
Sales:
–
Patents | Expiration Date |
---|---|
US7834020 | December 5, 2022 |
US8673921 | December 5, 2022 |
Dosage: Oral
Company: Allergan
Ingredients: VILAZODONE HYDROCHLORIDE
Treatment: Major depressive disorder
Taflotan
Tafluprost
Sales:
$180 Million (2020) Est.
Patents | Expiration Date |
---|---|
US5886035 | December 18, 2022 |
Dosage: Eye Drops
Company: Santen Pharmaceutical
Ingredients: TAFLUPROST
Treatment: Open-angle Glaucoma
Hetlioz
Tasimelteon
Sales:
$173.5 Million (2021)
Patents | Expiration Date |
---|---|
US5856529 | December 9, 2022 |
US10829465 | February 12, 2035 |
US10071977 | February 12, 2035 |
Dosage: Oral
Company: Vanda Pharmaceuticals
Ingredients: TASIMELTEON
Treatment: Non-24-hour sleep-wake disorder
An Excellent work was done, this data is really useful.
Descriptive data collection and presented well, Goog Job.
This data is an excellent collection, got the immediate requirement for strategic decisions.